Advanced Search
CASE REPORT
Korean J Pediatr 2009 January;52(1) :119-123.
doi:https://doi.org/10.3345/kjp.2009.52.1.119
Hand-Foot syndrome induced by sorafenib, a multitargeted tyrosine kinase inhibitor, in a patient with advanced renal cell carcinoma
Seung Hyun Lee (Lee SH)1, Sung Hun Noh (Noh SH)1, Sun Young Kim (Kim SY)1, Kyu Yun Jang (Jang KY)2, Pyoung Han Hwang (Hwang PH)1
1Department of Pediatrics, Research Institute of Clinical Medicine, School of Medicine, Chonbuk National University, Jeonju, Korea
2Department of Pathology, Research Institute of Clinical Medicine, School of Medicine, Chonbuk National University, Jeonju, Korea
Corresponding Author: Pyoung Han Hwang ,Email: hwaph@chonbuk.ac.kr.
Copyright © 2009 by The Korean Pediatric Society
ABSTRACT
Renal cell carcinoma (RCC) arising from epithelial cells of the renal tubules is a highly aggressive and malignant tumor in all ages; however, it rarely occurs in children. the standard treatment for RCC is radical nephrectomy with lymph node dissection when the tumor is localized and can be completely resected. Adjuvant chemotherapy, radiotherapy, and immunotherapy are used for pediatric patients with advanced RCC involving lymph nodes or metastatic lesions. Sorafenib is an oral, multikinase inhibitor that has recently been approved for use in metastatic RCC. Common toxicities that have been reported include dermatologic changes such as rash or desquamation and hand-foot skin reaction, diarrhea, fatigue, alopecia, and hypertension. In particular, hand-foot syndrome (HFS) an erythematous skin lesion of the palms and solesis most often caused by cytostatic chemotherapeutic agents. In this report, we have studied a 14-year-old female patient with hand-foot syndrome that occurred in association with sorafenib for the treatment of metastatic RCC. Furthermore, this case demonstrates that reversal of complications can be achieved by discontinuing the drug and intervention with topical steroids, vitamin E, and high-dose pyridoxine.
Keywords: Hand-Foot syndrome (HFS) | Sorafenib | Renal cell carcinoma
TOOLS
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
Supplementary Material  Supplementary Material
  E-Mail
  Print
Share:      
METRICS
1,343
View
0
Download
Register for e-submission
Register here to access the e-submission system of Korean J Pediatr for authors and reviewers.
Manuscript Submission
To submit a manuscript, please visit the Korean J Pediatr e-submission management system at http://submit.kjp.or.kr, read the Instructions for Authors, and log into the Korean J Pediatr e-submission system. For assistance with manuscript submission, please contact: kjpped@gmail.com.
Free archive
Anyone may access any past or current articles without logging in.
Korean Pediatric Society Office
#1606, Seocho World Officetel, 19 Seoun-ro, Seocho-gu, Seoul 137-070, Korea
TEL : +82-2-3473-7305    FAX : +82-2-3473-7307   E-mail: kjpped@gmail.com
BrowseCurrent IssueFor Authors and ReviewersAbout
Copyright© The Korean Pediatric Society. All right reserved.